List of Simbrinza drug patents

Simbrinza is owned by Alcon Labs Inc.

Simbrinza contains Brimonidine Tartrate; Brinzolamide.

Simbrinza has a total of 2 drug patents out of which 0 drug patents have expired.

Simbrinza was authorised for market use on 19 April, 2013.

Simbrinza is available in suspension/drops;ophthalmic dosage forms.

The generics of Simbrinza are possible to be released after 30 October, 2030.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9421265 ALCON LABS INC Aqueous pharmaceutical compositions containing borate-polyol complexes
Jun, 2030

(7 years from now)

US9044484 ALCON LABS INC Aqueous pharmaceutical compositions containing borate-polyol complexes
Oct, 2030

(7 years from now)

Drugs and Companies using BRIMONIDINE TARTRATE; BRINZOLAMIDE ingredient

Market Authorisation Date: 19 April, 2013

Treatment: NA

Dosage: SUSPENSION/DROPS;OPHTHALMIC

How can I launch a generic of SIMBRINZA before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in